EP1418918A4 - Compositions and methods for targeting cerebral circulation and treatment of headache - Google Patents

Compositions and methods for targeting cerebral circulation and treatment of headache

Info

Publication number
EP1418918A4
EP1418918A4 EP02753504A EP02753504A EP1418918A4 EP 1418918 A4 EP1418918 A4 EP 1418918A4 EP 02753504 A EP02753504 A EP 02753504A EP 02753504 A EP02753504 A EP 02753504A EP 1418918 A4 EP1418918 A4 EP 1418918A4
Authority
EP
European Patent Office
Prior art keywords
headache
compositions
treatment
methods
cerebral circulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02753504A
Other languages
German (de)
French (fr)
Other versions
EP1418918A2 (en
Inventor
Bruce Frome
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epitome Pharmaceuticals Ltd
Original Assignee
Epitome Pharmaceuticals Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitome Pharmaceuticals Ltd USA filed Critical Epitome Pharmaceuticals Ltd USA
Publication of EP1418918A2 publication Critical patent/EP1418918A2/en
Publication of EP1418918A4 publication Critical patent/EP1418918A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
EP02753504A 2001-08-23 2002-08-20 Compositions and methods for targeting cerebral circulation and treatment of headache Withdrawn EP1418918A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2001/026459 WO2003018023A1 (en) 2001-08-23 2001-08-23 Compositions and methods for targeting cerebral circulation and treatment of headache
WOPCT/US26/00459 2001-08-23
PCT/US2002/026613 WO2003017932A2 (en) 2001-08-23 2002-08-20 Compositions and methods for targeting cerebral circulation and treatment of headache

Publications (2)

Publication Number Publication Date
EP1418918A2 EP1418918A2 (en) 2004-05-19
EP1418918A4 true EP1418918A4 (en) 2006-11-29

Family

ID=21742800

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02753504A Withdrawn EP1418918A4 (en) 2001-08-23 2002-08-20 Compositions and methods for targeting cerebral circulation and treatment of headache

Country Status (3)

Country Link
EP (1) EP1418918A4 (en)
AU (1) AU2002313785A1 (en)
WO (2) WO2003018023A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175440A2 (en) * 1984-09-06 1986-03-26 Margaret N. Innes Method of treating migraine headaches
US4777174A (en) * 1982-07-22 1988-10-11 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
DE4241128A1 (en) * 1991-12-20 1993-06-24 Lohmann Therapie Syst Lts Transdermal aspirin dosage forms - for antithrombotic therapy or cancer prophylaxis
WO1997029735A1 (en) * 1996-02-19 1997-08-21 Monash University Dermal penetration enhancers and drug delivery systems involving same
WO2001089489A2 (en) * 2000-05-24 2001-11-29 Lts Lohmann Therapie-Systeme Ag Transdermal application of active agents directly via the carotid artery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777147A (en) 1987-01-28 1988-10-11 Texas Instruments Incorporated Forming a split-level CMOS device
US5250529A (en) * 1990-02-08 1993-10-05 Kos Pharmaceuticals, Inc. Method alleviating migraine headache with mast cell degranulation blocking agents
US5552406A (en) * 1994-06-17 1996-09-03 The Mclean Hospital Corporation Method for treating pain and brain perfusion abnormalities using mixed opioid agonist-antagonists
US5885597A (en) * 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777174A (en) * 1982-07-22 1988-10-11 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
EP0175440A2 (en) * 1984-09-06 1986-03-26 Margaret N. Innes Method of treating migraine headaches
DE4241128A1 (en) * 1991-12-20 1993-06-24 Lohmann Therapie Syst Lts Transdermal aspirin dosage forms - for antithrombotic therapy or cancer prophylaxis
WO1997029735A1 (en) * 1996-02-19 1997-08-21 Monash University Dermal penetration enhancers and drug delivery systems involving same
WO2001089489A2 (en) * 2000-05-24 2001-11-29 Lts Lohmann Therapie-Systeme Ag Transdermal application of active agents directly via the carotid artery

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO03017932A2 *
TOUITOU E. ET AL: "Enhanced permeation of theophylline through the skin and its effect on fibroblast proliferation", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 70, no. 1-2, 31 March 1991 (1991-03-31), ELSEVIER BV, NL, pages 159 - 166, XP023725205 *

Also Published As

Publication number Publication date
AU2002313785A1 (en) 2003-03-10
EP1418918A2 (en) 2004-05-19
WO2003017932A2 (en) 2003-03-06
WO2003018023A1 (en) 2003-03-06
WO2003017932B1 (en) 2003-09-12
WO2003017932A3 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
HK1091840A1 (en) Methods and compositions for therapeutic use of rna interference
EP1416961A4 (en) Composition and method for the treatment of disease
AU2002364364A8 (en) Method of treating apoptosis and compositions thereof
IL162153A0 (en) Methods and compositions for treatment of central nervous systemdisorders
EP1696910A4 (en) Compositions and methods for treatment of fibrosis
HUP0402075A3 (en) Compositions for treatment of common cold
EP1379242A4 (en) Method for treatment of cancer and compositions for use therein
EP1461090A4 (en) Composition and method for treatment of otitis media
EP1463495A4 (en) Agents and methods for treatment of cancer
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
IL145397A0 (en) Compositions and methods for treatment of cancer
AU2003272728A8 (en) Methods and compositions for treatment of neurological disorder
AU2002362115A8 (en) Composition and methods for treatment of neurological disorders
PL368035A1 (en) Compositions and methods for the treatment of cancer
EP1460967A4 (en) Composition and method for treatment of otitis externa
GB0124124D0 (en) Methods of treatment
EP1389105A4 (en) Method of treatment
EP1472273A4 (en) Compositions and methods for the treatment of immune related diseases
GB0112216D0 (en) Method of treatment
EP1418918A4 (en) Compositions and methods for targeting cerebral circulation and treatment of headache
EP1423118A4 (en) Method and composition for treatment of cancer
AU3712500A (en) Compositions and methods for treatment of epilepsy
AU2001286718A1 (en) Compositions and methods for targeting cerebral circulation and treatment of headache
GB0118892D0 (en) Method of treatment
GB0210264D0 (en) The treatment of pain and migraine headache

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040211

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EPITOME PHARMACEUTICALS LIMITED

A4 Supplementary search report drawn up and despatched

Effective date: 20061026

17Q First examination report despatched

Effective date: 20070205

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110301